A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
Financial Summary
| Share Statistics | PTKFY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,816.8 | $579.1 | 52% |
|
| Shares Out (Mil) | 2.7 | 43.0 | 9% |
|
| Institutional Ownership | 47.8% | 84.3% | 22% |
|
| Float (Mil) | 17,993.2 | 46.8 | 100% |
|
| Beta | 0.01 | 0.62 | 6% |
|
| Avg Daily Volume (000s) | 2 | 285 | 9% |
|
| Price Change (52-week) |
(58.7%) | 63.8% | 13% |
|
| Growth | PTKFY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.0% | 6.7% | 36% |
|
| Net Income (5yr) | 2.3% | (1.4%) | 43% |
|
| EPS (5yr) | 4.6% | 14.9% | 37 |
|
| Dividends (5yr) | (14.9%) | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.9%) | (14.9%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PTKFY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,136 | $272 | 61% |
|
| Net Income (TTM) (Mil) | $213 | ($11) | 69% |
|
| EPS (TTM) | $0.005 | ($0.500) | 39% |
|
| Operating Cash Flow (TTM) (Mil) | $188 | ($6) | 59% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $4 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $7 | 28% |
|
| Enterprise Value (Q1) (Mil) | $2,210 | $522 | 51% |
|
| Valuation | PTKFY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | PTKFY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 38.3% | 65.9% | 47% |
|
| Net Margin | 10.0% | 0.7% | 63% |
|
| ROA | 11.4% | (24.6%) | 89% |
|
| ROE | 15.0% | (19.7%) | 71% |
|
| Liabilities to Assets | 19.5% | 35.5% | 12% |
|
| F-Score | na | 3 | na |
|
PT Kalbe Farma Tbk. did not pass any screens on 7/31/2026.
